I-1000233 / IRBM - LARVOL DELTA

Advancing treatment for brain tumors and metastases with brain permeable SHP2 inhibitor I-1000233 (AACR 2025) - "I-1000233 is a potent, selective, and orally available SHP2 inhibitor with demonstrated efficacy in preclinical models of primary brain tumors and metastases. Its ability to penetrate the BBB, modulate the tumor microenvironment, and provide combinatory potential with other agents highlights its promise as a therapeutic candidate for treating SHP2-responsive brain cancers."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • EGFR • PTPN11

Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor (AACR 2024) - "I-1000233 is a potent, selective and orally available SHP2 inhibitor with potential for once-a-day dosing and its brain permeability in humans makes it a promising therapeutic agent against SHP2i responsive brain tumors and metastases."

Brain Cancer • Oncology • Solid Tumor • EGFR

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR (PRNewswire) - "IRBM...announced today that it will be disclosing new data on two of its most promising internal assets at the upcoming American Association for Cancer Research (AACR) Annual Meeting....Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in 'Ph-like' B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents. Potential best-in-class brain permeable SHP2 allosteric inhibitor (I-1000233) exhibited promising results in preclinical studies, offering a new method of treating patients with RAS-driven malignancies, including challenging brain tumors and metastases."

Preclinical • B Acute Lymphoblastic Leukemia • Brain Cancer